Provectus Pharmaceuticals (PVCT) Stock Statistics & Valuation Metrics
Total Valuation
Provectus Pharmaceuticals has a market cap or net worth of $20.93M. The enterprise value is $28.47T.
- Market Cap
- $20.93M
- Enterprise Value
- $28.47T
Share Statistics
Provectus Pharmaceuticals has 420,279,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 420,279,880
- Owned by Insiders
- 0.36%
- Owned by Institutions
- 0.03%
Financial Efficiency
Provectus Pharmaceuticals’s return on equity (ROE) is 0.86 and return on invested capital (ROIC) is 145.74%.
- Return on Equity (ROE)
- 0.86
- Return on Assets (ROA)
- -7.79
- Return on Invested Capital (ROIC)
- 145.74%
- Return on Capital Employed (ROCE)
- 0.78
- Revenue Per Employee
- 56.02K
- Profits Per Employee
- -905.14K
- Employee Count
- 6
- Asset Turnover
- 0.48
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Provectus Pharmaceuticals is -4.41. Provectus Pharmaceuticals’s PEG ratio is -0.17.
- PE Ratio
- -4.41
- PS Ratio
- 0.00
- PB Ratio
- -3.33
- Price to FCF
- -8.63
- Price to Operating Cash Flow
- -8.63
- PEG Ratio
- -0.17
Income Statement
In the last 12 months, Provectus Pharmaceuticals had revenue of 336.11K and earned -5.43M in profits. Earnings per share was -0.01.
- Revenue
- 336.11K
- Gross Profit
- 334.25K
- Operating Income
- -4.84M
- Pretax Income
- -5.51M
- Net Income
- -5.43M
- EBITDA
- -4.84M
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -2.43M and capital expenditures 0, giving a free cash flow of -2.43M billion.
- Operating Cash Flow
- -2.43M
- Free Cash Flow
- -2.43M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Provectus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -11.59%
- Earnings Yield
- -22.69%
Stock Price Statistics
- Beta
- -0.26
- 52-Week Price Change
- -30.99%
- 50-Day Moving Average
- 0.05
- 200-Day Moving Average
- 0.06
- Relative Strength Index (RSI)
- 48.21
- Average Volume (3m)
- 112.53K
Financial Position
Provectus Pharmaceuticals as a current ratio of 0.08, with Debt / Equity ratio of -47.26%
- Current Ratio
- 0.08
- Quick Ratio
- 0.08
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- -0.56
- Interest Coverage Ratio
- -23.03
Taxes
In the past 12 months, Provectus Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Provectus Pharmaceuticals EV to EBITDA ratio is -5.60, with an EV/FCF ratio of -9.60.
- EV to Sales
- 0.00
- EV to EBITDA
- -5.60
- EV to Free Cash Flow
- -9.60
- EV to Operating Cash Flow
- -9.60
Balance Sheet
Provectus Pharmaceuticals has $1.16M in cash and marketable securities with $3.51M in debt, giving a net cash position of -$2.35M billion.
- Cash & Marketable Securities
- $1.16M
- Total Debt
- $3.51M
- Net Cash
- -$2.35M
- Net Cash Per Share
- -$0.01
- Tangible Book Value Per Share
- -$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Provectus Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- 25.17%
